ANGO · Angiodynamics Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $13.2M | Year Ended May 31, 2026 | — |
|
|
|||
| Auryon sales | $16.3M | third quarter of fiscal year 2026 | — |
| Mechanical Thrombectomy sales | $11.5M | third quarter of fiscal year 2026 | — |
| Med Device Net Sales | $41.1M | third quarter of fiscal year 2026 | +1.1% |
|
|
|||
| Med Device Pro Forma YoY Growth | 1.1% | third quarter of fiscal year 2026 | — |
| Med Tech Net Sales | $37.3M | third quarter of fiscal year 2026 | +19.0% |
|
|
|||
| NanoKnife sales | $7.6M | third quarter of fiscal year 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANGO
this stock
Angiodynamics Inc
|
$655.12M | +23.4% | +10.2% | — | 3.0% |
|
ISRG
Intuitive Surgical Inc
|
$139.37B | -30.3% | +20.5% | 45.3 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$49.96B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$46.99B | -14.9% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.89B | -5.8% | +10.5% | — | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANGO | +1.0% | +17.3% | +41.4% | +7.2% | +23.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.6% | +12.9% | +27.6% | +3.3% | +9.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.